Project Kick-Off Meeting Sets the Stage for Success
Our project “Multiplex8+: Prospective clinical validation of a highly accurate BCa diagnostic test to guide personalised-effective treatment, predict therapy response and prognosis” has officially launched with a successful kick-off meeting, where key team members gathered to align on goals, timelines, and responsibilities. During the meeting, we outlined the project scope, identified key milestones, and discussed potential risks and solutions. With clear communication channels and action items set, the team is now fully prepared to move forward and execute the plan.
MultiplexDX is proud to announce that our project has been awarded the prestigious Seal of Excellence, recognizing our work's high quality and innovation. This mark of excellence affirms our commitment to delivering exceptional results and sets the stage for continued success as we move forward. Following this success, our project has received funding from the Resilience and Recovery Plan, managed by the Ministry of Economy of the Slovak Republic. This funding will support the continued development and success of our research activities, enabling us to drive innovation and contribute to economic growth. We are excited for the journey ahead and look forward to achieving success together!
Funded by the EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia under the project No. 09I01-03-V01-00003.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
